S-ClassAbout S-Class
T
TEVAAI Stock Diagnostic Report
Teva gains approval of monthly olanzapine injection for schizophrenia
Teva is expected to create new sales opportunities after securing approval for a monthly olanzapine injection to treat schizophrenia.
View Source Article ↗AI CATALYST SCORE75 / 100Score computed by Sentinel V12
REFERENCE PRICE$41.58Reference entry price at analysis time
01
MARKET SNAPSHOT
Key Indicators at a Glance
Major Support36.06
Near-Term Resistance40.79
02
FUNDAMENTALS
Financial & Fundamental Analysis
Potential to diversify the core portfolio and secure medium- to long-term sales growth drivers through new drug approvals.
03
TECHNICAL VIEW
Technical Position & Response Criteria
The stock price is currently breaking above the 20-day resistance line ($40.79), with buying pressure flowing in above the support line ($36.06).
Support36.06
Resistance40.79
04
CATALYST & STRATEGY
Catalyst Analysis & Forward Strategy
The approval of the monthly olanzapine injection during the adjustment period is a strong catalyst that enhances the visibility of actual product commercialization.
05
PROOF OF WORK
Analysis Point vs. Subsequent Price Action
INITIAL · At Analysis (2026-10-09)
FINAL · Current/Verified
Renders the actual stored OHLC data directly in your browser.